+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating different dose levels of Brenipatide in adults with moderate-to-severe Chronic Obstructive Pulmonary Disease COPD. The study aims to assess the safety and effectiveness of Brenipatide compared to a placebo over approximately one year. This Phase 2 trial focuses on how the drug works alongside standard care in people with COPD who have a history of smoking and recent exacerbations. Participants are randomly assigned to receive either a low dose or high dose of Brenipatide or a placebo, all given by subcutaneous injection. All groups continue their standard care therapy, which may include long-acting bronchodilators or inhaled corticosteroids. The treatment period lasts 52 weeks, during which participants receive the study drug or placebo alongside their regular medications. Throughout the study, participants will have lung function tests measuring forced expiratory volume FEV1 before bronchodilator use at baseline and at several weeks up to week 52. Researchers will also monitor COPD exacerbation rates and quality of life using specific questionnaires. Safety and treatment effects are assessed regularly to understand how Brenipatide performs in managing COPD symptoms and lung function over one year.

Age: 40Years - 75YearsAll GendersPhase 2
127 locations
E

Actively Recruiting

Researchers are evaluating the safety and effects of a study medicine called PF-07275315 for treating adults with moderate-to-severe asthma that is not well controlled. Asthma is a condition that makes breathing difficult and affects quality of life. This phase 2 clinical trial includes participants aged 18 to 75 who have had moderate-to-severe asthma for at least 12 months and have been on maintenance asthma treatment for the past 6 months. Participants will receive either PF-07275315 or a placebo, both given as multiple subcutaneous injections in the clinic over 12 weeks. The study compares experiences between those receiving the study medicine and those receiving placebo to assess safety and effects. The trial is randomized, double-blind, and placebo-controlled with parallel groups. During the study, participants will be involved for up to approximately 9.5 months depending on local regulations. They will have regular visits for injections and assessments including lung function tests like FEV1, questionnaires about asthma control and quality of life, and safety monitoring through lab tests, vital signs, and electrocardiograms. Researchers will track changes from baseline in lung function and adverse events up to 24 weeks after treatment begins.

Age: 18Years - 75YearsAll GendersPhase 2
137 locations